Abstracts tagged "gout"

Abstract Number: 1298 • 2018 ACR/ARHP Annual Meeting
Gout and the Risk of Parkinson’s Disease in Older Adults: A Study of U.S. Medicare Data
Jasvinder A. Singh and John Cleveland, Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: In the presence of limited available data, our objective was to assess the association of gout with the risk of incident Parkinson’s disease (PD)…
Abstract Number: 2965 • 2018 ACR/ARHP Annual Meeting
Targeting Glucose Metabolism in the Murine Air Pouch Model of Acute Gouty Inflammation
Anyan Cheng¹, Roxana Coras^1,2, Robert Terkeltaub^3,4, Ru Liu-Bryan^1,3 and Monica Guma^1,2, ¹Medicine, University of California San Diego, La Jolla, CA, ²Medicine, Autonomous University of Barcelona, Bellatera, Spain, ³VA San Diego Healthcare System, San Diego, CA, ⁴Medicine, Division of Rheumatology, Allergy and Immunology. UCSD., La Jolla, CA
Background/Purpose: Emerging evidence indicates that macrophage activation is critically supported by glucose metabolic shifts. Although macrophages are key contributors to inflammation, little is known about…
Abstract Number: 197 • 2018 ACR/ARHP Annual Meeting
Improving Clinical Decisions for Gout Management: Effect of Online Case-Based Education
Nimish Mehta, Piyali Chatterjee-Shin and Karen Badal, Medscape, LLC, New York, NY
Background/Purpose: Gout is a chronic condition with a considerable effect on patient health and quality of life. Despite the availability of multiple pharmacologic treatments and…
Abstract Number: 1247 • 2018 ACR/ARHP Annual Meeting
Pharmacist-Managed Titration of Urate-Lowering Therapy to Streamline Gout Management
Irvin Huang¹, Jean Liew², Meredith Barnes³, Silu Zuo⁴, Carol Crawford⁴ and Alison Bays⁵, ¹Internal Medicine, Boise VAMC, Boise, ID, ²Internal Medicine; Division of Rheumatology, University of Washington, Seattle, WA, ³Medicine, University of Washington, Seattle, WA, ⁴Harborview Medical Center, Seattle, WA, ⁵Division of Rheumatology, University of Washington, Seattle, CA
Background/Purpose: The treat-to-target approach for serum uric acid is the recommended model in gout management according to the 2012 American College of Rheumatology (ACR) guidelines.…
Abstract Number: 2217 • 2018 ACR/ARHP Annual Meeting
Clinical Characteristics of Early Onset Gout in Outpatient Setting
Yan Li¹, Paramarajan Piranavan¹, Devi Sundaresan² and Robert A. Yood³, ¹Internal Medicine, St. Vincent Hospital, Worcester, MA, ²Research, Reliant Medical Group, Worcester, MA, ³Reliant Medical Group, Worcester, MA
Background/Purpose: There has been an increase in the prevalence of gout over the past two decades, with increasing number of patients presenting at younger age.…
Abstract Number: 2966 • 2018 ACR/ARHP Annual Meeting
Ultrasound Shows Rapid Reduction of Uric Load during Treat-to-Target Approach in Gout Patients: Results from a Longitudinal Study
Hilde B Hammer¹, Lars Fritjof Karoliussen², Lene Terslev³, Espen A. Haavardsholm¹, Tore Kvien⁴ and Till Uhlig⁵, ¹Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Dept of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ³Rheumatology, Rigshospitalet Glostrup, Copenhagen, Denmark, ⁴RAID working group for EULAR, Zurich, Switzerland, ⁵Rheumatology, Diakonhjemmet Hospital, Oslo, Norway
Background/Purpose: Uric monosodium urate (MSU) depositions are detected by ultrasound (US), and US is included in the ACR/EULAR classification criteria for gout. OMERACT definitions for…
Abstract Number: 268 • 2018 ACR/ARHP Annual Meeting
The Effect of Renaming Gout to Urate Crystal Arthritis on Illness and Treatment Perceptions in Māori (the Indigenous People of Aotearoa/New Zealand)
Nicola Dalbeth¹, Meihana Douglas¹, Kate MacKrill¹, Leanne Te Karu², Maria Kleinstäuber¹ and Keith Petrie¹, ¹University of Auckland, Auckland, New Zealand, ²Ngā Kaitiaki o Te Puna Rongoā o Aotearoa, Taupō, New Zealand
Background/Purpose: Recent research has suggested that renaming gout to a pathophysiological illness label (urate crystal arthritis) avoids inaccurate lay perceptions of gout and promotes…
Abstract Number: 1260 • 2018 ACR/ARHP Annual Meeting
Predictors of Hospitalization Due to Acute Gout: A Retrospective Cohort Study
Nadine Mbuyi¹, Isha Shah², Steven Reinert³, Grayson Baird⁴, Pieusha Malhotra⁵, Ross Hilliard⁶ and Deepan Dalal⁷, ¹Rheumatology, The Warren Alpert Medical School of Brown University, Providence, RI, ²Internal Medicine, The Warren Alpert Medical School of Brown University, Providence, RI, ³Lifespan Information Services, Lifespan Information Services, Providence, RI, Providence, RI, ⁴Department of Biostatistics, Lifespan, Rhode Island Hospital, Providence, RI, ⁵Rheumatology, Roger William Medical Center, Providence, RI, Providence, RI, ⁶Medicine, The Warren Alpert Medical School of Brown University, Providence, RI, ⁷Medicine/Rheumatology, The Warren Alpert Medical School of Brown University, Providence, RI
Background/Purpose: Despite effective treatments, hospitalization due to acute gout is increasing and is financially burdensome. Prior studies have primarily attributed the increased rate of gout…
Abstract Number: 2219 • 2018 ACR/ARHP Annual Meeting
Safety, Pharmacokinetics and Pharmacodynamics of NC-2500, a Novel Xanthine Oxidoreductase Inhibitor, in Healthy Volunteers
Masuharu Hirano¹, Shiro Kobayashi², Eri Miyayama², Takashi Ohta¹, Masao Yamamoto² and Tomio Yamakawa³, ¹Discovery Research Laboratories, Nippon Chemiphar Co., Ltd., Misato, Saitama Prefecture, Japan, ²Development Planning Department, Nippon Chemiphar Co., Ltd., Chiyoda-ku, Tokyo, Japan, ³Discovery Research Laboratories, Nippon Chemiphar Co., Ltd., Misato, Saitama prefecture, Japan
Background/Purpose: Gout flare due to rapid urate reduction after initiating urate-lowering therapy (ULT) is one of the major issues in the therapy. International guidelines recommend…
Abstract Number: 2967 • 2018 ACR/ARHP Annual Meeting
Potent Bifunctional Inhibitors of Xanthine Oxidase and URAT1 Block Fructose-Induced Inflammation Via Increase in AMP Kinase Activity
Laura Gabriela Sánchez Lozada¹, Fernando E. García-Arroyo², J. Gabriel Juárez-Rojas³, Guillermo Gonzaga² and Raymond P. Warrell Jr.⁴, ¹Nephrology, INC Ignacio Chavez, Mexico City, Mexico, ²INC Ignacio Chavez, Mexico City, Mexico, ³INC Ignacio Chavez, Mexoci City, Mexico, ⁴Relburn-Metabolomics, Inc., Westfield, NJ
Background/Purpose: Dietary fructose promotes an increase in uric acid (UA) that may lead to gout. UA itself promotes lipogenesis and inflammation in both gout as…
Abstract Number: 433 • 2018 ACR/ARHP Annual Meeting
Impact of Bariatric Surgery on Rheumatic Diseases: A Systematic Review and Meta-Analysis
Marie Moly¹, Bernard Combe¹, Thomas Barnetche², Claire Daien¹, Jacques Morel³, Cédric Lukas¹, Cécile Gaujoux-Viala⁴ and Charlotte Hua⁴, ¹Rheumatology, University Hospital Lapeyronie, Montpellier, Montpellier, France, ²Rheumatology, University Hospital Pellegrin, Bordeaux, Bordeaux, France, ³Department of Rheumatology, University Hospital Lapeyronie, Montpellier, Montpellier, France, ⁴Rheumatology, University Hospital Carémeau , Nimes, Nimes, France
Background/Purpose: Obesity increase the incidence of rheumatic diseases (1-3). Bariatric surgery (BS) improve obesity-related comorbidities (4). The aim of our study was to assess currently…
Abstract Number: 1265 • 2018 ACR/ARHP Annual Meeting
The Challenges of Managing Gout in Primary Care: Results of a Best Practice Audit
Lisa K. Stamp¹, Peter T. Chapman², Ben Hudson³, Greg Hamilton⁴ and Andrea Judd⁵, ¹University of Otago, Christchurch, New Zealand, ²Christchurch Hospital, Christchurch, New Zealand, ³University of Otago, Christchurch, Christchurch, New Zealand, ⁴Canterbury District Health Board, Christchurch, New Zealand, ⁵Kaikoura Medical Centre, Kaikoura, New Zealand
Background/Purpose: The majority of gout management occurs in primary care and may be suboptimal. While community based clinical trials have reported improvements whether such improvements…
Abstract Number: 2222 • 2018 ACR/ARHP Annual Meeting
Construct Validity of Provisional Remission Criteria for Gout: A Dual Energy CT Study
Nicola Dalbeth¹, Christopher Frampton², Maple Fung³, Scott Baumgartner³, Savvas Nicolaou⁴ and Hyon K. Choi⁵, ¹University of Auckland, Auckland, New Zealand, ²University of Otago, Christchurch, New Zealand, ³Formerly Ardea Biosciences, San Diego, CA, ⁴Radiology, University of British Columbia, Vancouver, BC, Canada, ⁵Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Boston, MA
Background/Purpose: Provisional domains and definitions for gout remission criteria have been proposed using consensus methodology (de Lautour et al, Arthritis Care Res 2016). These criteria…
Abstract Number: 869 • 2018 ACR/ARHP Annual Meeting
Failure to Reach Serum Urate Target Is Associated with Elevated Mortality in Gout
Fernando Perez-Ruiz^1,2,3, Pascal Richette^4,5, Austin Stack⁶, Ravichandra Karra Gurunath⁷, MARIA JESUS GARCIA DE YEBENES Y PROUS⁸ and Loreto Carmona⁹, ¹Rheumatology Division, Hospital Universitario Cruces, Baracaldo, Spain, ²University of the Basque Country (UPV/EHU), Bilbao, Spain, ³BioCruces Health Research Institute, Barakaldo, Spain, ⁴Lariboisière Hospital, Lariboisière, University of Paris 7, Paris, France, ⁵Rheumatology, Université Paris Diderot, Paris, France, ⁶Nephrology, University Hospital Limerick & Health Research Institute,University of Limerick, Limerick, Ireland, ⁷Grünenthal GmbH, Aachen, Germany, ⁸Institute for Musculoskeletal Health, Madrid, Spain, ⁹Instituto de Salud Musculoesquelética (InMusc), Madrid, Spain
Background/Purpose: Gout is associated with an increased risk of cardiovascular events and death. It has been shown that both overall and risk of death are…
Abstract Number: 1271 • 2018 ACR/ARHP Annual Meeting
Predictive Factors of Increased Vascular Stiffness in Patient with Gout and Hyperuricemia
WooSeong Jeong¹, Jinseok Kim², Joon Hyouk Choi³ and Byeongzu Ghang¹, ¹Division of Rheumatology, Department of Internal Medicine, Jeju National University Hospital, University of Jeju School of Medicine, Jeju, Korea, Republic of (South), ²Department of Medicine, Jeju National University Hospital, University of Jeju School of Medicine, Jeju, Korea, Republic of (South), ³Division of Cardiology, Department of Internal Medicine, Jeju National University Hospital, University of Jeju School of Medicine, Jeju, Korea, Republic of (South)
Background/Purpose: Background: Gout is the most common form of inflammatory arthritis and its prevalence is increasing in more affluent countries in recent decades. Many studies…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].